Skip to main content

Table 2 Multivariate analyses (Cox model) on PFS and OS

From: Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

  Progression-free survival Overall survival
HR (IC95%) p-value HR (IC95%) p-value
EUA 1.6 (0.6–2.2) 0.645 2.2 (1.1–4.8) 0.038
PS 2 2.1 (1.1–4.1) 0.023 1.8 (0.7–4.4) 0.198
Hg rate (continuous) 0.8 (0.0–0.9) 0.005 0.8 (0.6–1.1) 0.174
Alb rate < 30 g/dl 1.1 (0.5–2.3) 0.908 0.5 (0.2–1.5) 0.216
Kras mutation 0.7 (0.4–1.2) 0.181 0.4 (0.0–0.9) 0.020
PDL1 ≥ 1% 1.6 (0.6–4.2) 0.295 3.0 (0.9–10.8) 0.085
Citrulline < 20 μM 3.8 (1.4–99.9) 0.008 2.4 (0.6–10) 0.222
Presence of Gemmatimonadaceae 2.9 (0.9–9.2) 0.073 16.4 (3.9–68.5) < 0.001
  1. HR hazard ratio, EUA early use of antibiotics, PS Performance status, Hg hemoglobin, Alb albumin